Clinical Trials Logo

Clinical Trial Summary

Rheumatoid arthritis (RA) has been proved to increase the incidence of atrial fibrillation (AF) with persistent systemic inflammation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been found to enhance the production of pro-inflammatory cytokines. Therefore, we performed the present study to observe the expression and significance of proprotein convertase subtilisin kexin 9 (PCSK9) in patients with RA combined atrial fibrillation.


Clinical Trial Description

Atrial fibrillation (AF), the most common clinically relevant arrhythmia, is an important contributor to population morbidity and mortality. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, which affects approximately 1% of the population. Increasing studies demonstrated that RA had a positive correlation with increased cardiovascular diseases. Increasing studies showed that the prevalence of AF is significantly higher in RA patients than in the general population. Recently, some studies indicated that proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes inflammatory by regulating macrophage secretion of inflammatory cytokines, inducing C-reaction protein (CRP), interleukin (IL)-6, IL-8, tumor necrosis factor-α (TNF-α) and so on. However, the levels of PCSK9 in atrial fibrillation patients with rheumatoid arthritis is still unclear. Therefore, the aim of this study was to assess the expression of PCSK9 in patients with RA combined atrial fibrillation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05191342
Study type Observational
Source First Affiliated Hospital of Harbin Medical University
Contact Meijiao He, Doctor
Phone 86-451-85555673
Email [email protected]
Status Recruiting
Phase
Start date November 1, 2021
Completion date November 1, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04759534 - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia Phase 3
Completed NCT02514070 - Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults Phase 2
Completed NCT03139630 - COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV—Infected Patients N/A
Completed NCT03043365 - Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults Phase 2